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Many studies have reported increased expression of S100 A7 (psoriasin) in neoplastic lesions. 
Among them are studies on breast carcinoma, bladder squamous cell carcinoma, skin tumors and 
oral cavity squamous cell carcinoma. The expression of S100 A7 has not been described for laryngeal 
cancer.
Objective: This study aims to identify the expression of the calcium-binding protein S100 A7 and 
its correlation with squamous cell carcinomas of the larynx.
Material and Methods: Specimens from 63 patients were submitted to immunohistochemistry testing 
with antibody S100 A7. Results were classified and compared.
Results: The group with highly differentiated tumors had the highest treatment failure scores. 
Moderately differentiated tumors had higher treatment failure scores than poorly differentiated 
tumors. Higher scores were predominantly seen on stages I and II in moderately differentiated 
tumors, whereas score distribution was more homogeneous in advanced stage disease (III and IV). 
Regarding failure in treatment, the group scoring zero (3/4 complications: 75%) differed significantly 
from the remaining groups (13/59: 22%).
Conclusions: S100 A7 marker was expressed in 93.7% of laryngeal cancer cases, with higher positive 
correlation rates in more differentiated tumors and significantly lower rates of treatment failure. 
Scores had no impact on survival rates.
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INTRODUCTION
Despite the multiple advances in the diagnosis and 
treatment of laryngeal tumors, the survival rate of affected 
patients has increased little over the last 30 years. This is 
believed to be due to the heterogeneous course of the 
disease, and it is of fundamental importance to identify the 
most aggressive ones in order to improve their cure rate 
by applying a specific treatment. Many clinical and histo-
pathological characteristics that might define this group 
of tumors have been intensely studied, with emphasis on 
cellular and molecular alterations over the last few years, 
although without success1.
The study of the psoriasin protein is still in an 
early stage2; however, its presence in urine suggests that 
it is a noninvasive marker capable of identifying cases of 
cancer and, according to Skliris et al.3, by being regulated 
by the activity of the estrogen receptor, this gene may 
represent a guide for target therapy. Frequent reports of 
increased expression of this gene in neoplastic lesions 
have been published. Among them are studies of ductal 
carcinoma of the breast, spinocellular carcinoma of the 
bladder, skin tumors and spinocellular carcinoma of the 
oral cavity4,5.
On this basis, the objective of the present study was 
to identify the immunohistochemical expression of the 
psoriasin S100 A7 in spinocellular carcinomas of the larynx 
(SCCL) and its correlation with demographic variables of 
the patients and with the histological characteristics of the 
tumor. An additional objective was to compare the overall 
survival curves of patients who express this gene to those 
of patients who do not express it.
MATERIALS AND METHODS
We selected 63 patients with a histopathological 
diagnosis of SCCL surgically treated who gave written in-
formed consent to participate in the study (Protocol CEP 
nº 9371/2003). Inclusion criteria were the availability of 
a representative tissue sample for histological processing, 
a precise definition of the primary tumor site, and com-
plete clinical and follow-up data. The specimens were 
routinely processed for anatomopathological study. The 
clinical, sociodemographic, anatomopathological and 
follow-up data of these patients were stored in a data 
control system.
For the immunohistochemical reactions, serial 4 
mm sections were obtained from the representative block 
and mounted on slides with an adhesive 3-amino-propyl-
triethoxy-silane solution (Sigma Chemical Co.®, St. Louis, 
MO). The sections were submitted to antigen retrieval with 
heat for 3 minutes in a steamer using a 10 mM citric acid 
solution, pH 6.0. Endogenous peroxidase was blocked 
with a 6% aqueous solution of hydrogen peroxide. The 
antibody used for the immunohistochemical reaction was 
S 100 A7 (psoriasin) - liquid mouse monoclonal antibody 
NCL-L-S100 A7 (Novocastra Laboratories, Newcastle-upon-
-Tyne, UK). A dextran polymer and the NovoLink enzyme 
amplification system (Novocastra) were used to prevent 
an endogenous reaction due to the presence of biotin 
and avidin. The material was incubated with the primary 
antibody at 37°C in a moist chamber overnight and with a 
secondary antibody diluted in PBS for 30 minutes at 37°C. 
After washing with PBS, the slides were incubated with the 
Novolink amplifier system at 37°C for 30 minutes. Finally, 
the sections were washed in running water for 10 minutes, 
counterstained with Harris hematoxylin for 10 seconds, 
washed again in running water, dehydrated with ethanol, 
cleared with xylene, and mounted with Permount resin 
(code S15-100, Fisher Scientific®, Fair Lawn, NJ). Positive 
controls (normal skin) were used for each reaction batch. 
Negative controls (blanks) were prepared by replacing the 
primary antibody with PBS.
The reactions were examined by two pathologists 
who were unaware of the cases and defined by consensus. 
The reaction were scored subjectively as zero (up to 5% of 
the neoplastic cells labeled), 1+ (5-25%), 2+ (25-50%), 3+ 
(50-75%), and 4+ (more than 75%) (Figure 1). A positive 
immunolabeling above 5% was considered for statistical 
analysis.
Figure 1. Larynx’s specimen of spinocellular carcinoma after immuno-
hystochemical reaction with expression of psoriasin S100 A7. Escores 
1+, 2+, 3+ and 4+ (Zoom 100X).
The different reaction scores obtained were compa-
red to the clinical, histopathological and follow-up data of 
the patients. Data were analyzed statistically by nonparame-
tric methods since the score variable did not show a normal 
distribution. The score variable was analyzed as a numerical 
variable. The level of significance was set at p ≤ .05.
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RESULTS
Characteristics of the Sample
The sample consisted of 63 patients, 58 men aged 
27 to 78 years (mean; 57.46 years) and five women aged 
47 to 59 years (mean; 53.2 years). Most patients had tumors 
located in the supraglottis (36 case) and in the glottis (24 
cases), with a respective incidence of 57 and 38%. Only 
three cases (4.7%) had tumors originating in the subglottis. 
Regarding clinical stage, eight cases were stage I, eight 
were stage II, 22 were stage III, and 25 were stage IV, three 
of them being IVb. The glottic tumors were distributed 
among all stages, with eight of them being classified as 
stage I; among the supraglottic tumors, 15 were stage III 
and 15 were stage IV. Only two of the 63 patients were 
non-smokers and 52 were alcohol drinkers.
Of the 63 patients studied, 17 (27%) died, 11 of them 
(17.4%) due to the neoplasia and six (9.5%) due to causes 
not related to the neoplasia. Local recurrence occurred in 
10 cases, seven patients had regional recurrence and one 
had distant metastases. A second primary tumor occurred 
in five cases.
All tumors were classified histologically according 
to degree of differentiation, with 13 (20.6%) being well 
differentiated (WD), 37 (58.7%) moderately differentiated 
(MD), and 13 (20.6%) poorly differentiated (PD). Most of 
the glottic tumors (91.7%) were moderately differentiated 
(16/24 = 66.7%) or well differentiated (6/24 = 25%) and 
only two were poorly differentiated. The supraglottic 
tumors were more uniformly differentiated, with seven 
(19.4%) being well differentiated, 19 (52.7%) moderately 
differentiated and 10 (27.8%) poorly differentiated. Among 
the subglottic tumors, two were moderately differentiated 
and one was poorly differentiated.
Score Determination
The score was 0+ for four cases (6.3%), 1+ 
for 10 cases (15.9%), 2+ for 15 cases (23.8%), 3+ 
for 10 cases (15.9%), and 4+ for 24 cases (38.1%). 
The scores obtained (Table 1) were related to the cli-
nical and sociodemographic variables of the patients 
and to the histopathological characteristics of the tu-
mors. The distribution of the scores was quite similar 
for the various anatomical sites, except for the subglot-
Table 1. Score distribution, degree of differentiation, tumor location, stage, failure in treatment and follow up of studied patients.
Patient Score Degree of Differentiation Tumor location Stage Failure+ Complication Follow up
1 4+ WD Supraglottic III DFS
2 2+ MD Supraglottic IVa LR + SPC Death from cancer
3 4+ MD Subglottic IVa DFS
4 4+ MD Supraglottic III LR Death from cancer
5 4+ MD Glottic IVa DFS
6 4+ MD Glottic IVa LR + NR Death from cancer
7 1+ PD Supraglottic III DFS
8 4+ MD Glottic I DFS
9 2+ MD Supraglottic III DFS
10 4+ MD Supraglottic II DFS
11 1+ PD Supraglottic II DFS
12 2+ MD Supraglottic IVa Death from surgery
13 3+ MD Glottic IVa SPC DFS
14 3+ MD Supraglottic II LR + NR Death from cancer
15 Zero PD Supraglottic III DFS
16 1+ PD Supraglottic II DFS
17 Zero PD Glottic III LR + NR Death from cancer
18 4+ MD Supraglottic IVa DFS
19 4+ MD Supraglottic IVb DFS
20 3+ MD Glottic II DFS
21 2+ MD Glottic I Death from other causes
22 1+ MD Supraglottic III Death from other causes
23 1+ PD Supraglottic II DFS
24 4+ WD Supraglottic III Distant Metastases Death from cancer
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25 2+ PD Supraglottic IVa Death from surgery
26 1+ PD Supraglottic IVa SPC DFS
27 3+ MD Glottic I DFS
28 4+ WD Glottic I DFS
29 3+ MD Subglottic IVa DFS
30 Zero PD Supraglottic III LR + NR DFS
31 2+ MD Supraglottic III DFS
32 1+ MD Supraglottic IVa DFS
33 4+ WD Glottic I DFS
34 1+ PD Supraglottic IVa LR Death from cancer
35 2+ PD Supraglottic IVa DFS
36 2+ MD Supraglottic III DFS
37 2+ MD Glottic I SPC Death from cancer
38 2+ MD Glottic III LR + NR DFS
39 3+ WD Subglottic III Death from other causes
40 4+ WD Supraglot II DFS
41 4+ WD Glottic III Death from other causes
42 4+ MD Glottic I DFS
43 4+ WD Glottic IVa DFS
44 4+ WD Supraglottic IVa Death from surgery
45 4+ WD Supraglottic IVa DFS
46 4+ WD Supraglottic III Death from other causes
47 4+ MD Supraglottic IVa NR Death from cancer
48 1+ PD Glottic IVa DFS
49 2+ MD Glottic III DFS
50 2+ MD Glottic IVa DFS
51 4+ WD Glottic I LR DFS
52 3+ MD Glottic III DFS
53 3+ MD Supraglottic III DFS
54 Zero MD Glottic IVb LR + NR DFS
55 4+ MD Supraglottic IVa DFS
56 3+ MD Supraglottic III DFS
57 4+ WD Glottic II DFS
58 2+ PD Supraglottic III DFS
59 4+ MD Glottic IVa DFS
60 2+ MD Supraglottic IVa SPC DFS
61 3+ MD Supraglottic III DFS
62 1+ MD Glottic III DFS
63 2+ MD Supraglottic IVa DFS
Continuation Table 1.
LR: Local Recurrence; NR: Neck Recurrence; SPC: Second Primary Cancer; DFS: Disease Free Survival; WD: Well differentiated; MD: Moderately 
Differentiated; PD: Poorly Differentiated.
tis due to the scarce number of cases. Glottic tu-
mors tended to be classified as 3+ and 4+ (15 of 24), 
whereas the supraglottic tumors tended to have a low 
score (20 of 36).
The score was compared to the degree of cell diffe-
rentiation by the nonparametric Kruskal-Wallis test, whose 
results are presented in Table 2. There was a statistically 
significant difference between groups. The score for the 
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Table 2. Distribution of the scores according the degree of cell 
differentiation by the nonparametric Kruskal-Wallis test.
Degree of 
Differentiation N Median Maximum Minimum Mean SD
PD 13 1.00 2.00 0.00 1.00 0.71
MD 37 3.00 4.00 0.00 2.76 1.09
WD 13 4.00 4.00 3.00 3.92 0.28
χ2 = 32.90, p < .001*, N: Number of individuals; SD: Standard de-
viation; PD: Poorly differentiated; MD: Moderately differentiated; WD: 
Well differentiated.
Table 3. Score distribution according to the tumor stages for 
MD Tumors.
Staging* Score 0/1+/2+ Score 3+/4+
I/II 2 6
III/IV (IVa and IVb) 14 14
MD: Moderately differentiated;
* TNM (American Joint Committee on Cancer).
Table 4. Score distribution according to presence of failure in 
treatment (local or regional recurrence, metastases and second 
primary tumor).
Score Number of Patients Failure in Treatment
Zero 4 3
1+ 10 2
2+ 15 6
3+ 10 2
4+ 24 5
analyzed separately or as a whole. Two groups were 
considered for the comparison of the survival curves ob-
tained between score groups: group 1 with absent or low 
positivity (considering zero, 1+ and 2+ scores) and group 
2 with strong positivity (considering 3+ and 4+ scores).
DISCUSSION
Psoriasin S100 A7 expression was observed in 93.7% 
of the samples analyzed and its scores were distributed 
among the various anatomical sites, except the subglottis 
due to the small number of cases. Glottic tumors showed 
a greater tendency to be classified as 3 and 4+ (15/24 
= 62.5%), whereas supraglottic tumors tended to show 
lower immunolabeling scores (20/36 = 55.5%). Poorly 
differentiated tumors received lower scores. This explains 
the greater tendency of glottis tumors to receive a higher 
score since more of them were well differentiated. Simi-
larly, supraglottic tumors had lower scores since more of 
them were poorly differentiated, although no significant 
difference in score was observed in relation to tumor site. 
This fact is explained by the probable function of this gene, 
which acts while the cells are well differentiated. As stated 
by Moubayed et al.4, this gene does not seem to have a 
function in undifferentiated tumors.
Of the 37 moderately differentiated tumors, 19 
(19/36 = 53.7%) were located in the supraglottis, 16 (16/24 
= 66.6%) in the glottis and 2 in the subglottis. Most of 
these tumors (56.7%, 21/37) were classified as more than 
2+; however, analysis of their distribution according to 
clinical stage revealed that those classified as stage I or 
II tended to obtain a score of more than 2+ (6/8), while 
those classified as stages III and IV showed a more uniform 
score distribution. In other words, the scores decreased 
with increasing tumor mass. Thus, the action of the pso-
riasin gene seems to be concentrated in the early phases 
of carcinogenesis.
Rigopoulou et al.6 detected susceptibility factors 
for papillary thyroid carcinoma that varied according to 
the populations investigated (Spaniards, Americans and 
Germans), showing that this susceptibility depended on 
genetic and environmental factors. This analysis was not 
possible in the present study because only two patients 
were non-smokers. No effect of alcohol drinking on pso-
riasin gene expression was detected here among alcoholic 
patients. Also, no significant relation was observed betwe-
en patient age and tumor score.
Although the clinical follow-up of the present 
patients was shorter than that recommended in the litera-
ture, comparison of survival rates according to the scores 
obtained (analyzed individually or in groups) did not 
demonstrate a statistically significant difference.
Failure in Treatment
The survival of the present sample was 73% (46/63) 
and the death rate was 27% (17/63 = 27%). Death was 
due to failure in treatment in 12.7% (8/63), complications 
WD group was significantly higher than the score for the 
MD and PD groups and the MD group had significantly 
higher scores than the PD group (WD > MD > PD). Po-
orly differentiated tumors were in the low score range, 
i.e., none of them had a 3 or 4+ score. Considering only 
moderately differentiated tumors, analysis of the score in 
relation to staging is presented in Table 3, where stages I 
and II, stages III and IV and scores 0, 1 and 2+ and 3 and 
4+ are grouped.
No significant relations were detected between the 
scores and the following variables: tumor site, clinical 
stage, patient age, presence of regional and/or local recur-
rence, second primary tumor, and death. Table 4 shows 
the correlations between failure in treatment such as the 
presence of local or regional recurrence, metastases and 
a second primary tumor and the different scores. There 
was a statistically significant difference (p = .02) between 
a zero score (3/4 = 75%) and the remaining ones (15/59 
= 25.4%) and failure in treatment.
The various curves were compared by the Kaplan-
-Meier method and the log rank test. No significant diffe-
rence in the survival was observed when the scores were 
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related to treatment in 4.7% (3/63), and to other causes in 
9.5% (6/63). Thus, 64.7% (11/17) of the deaths were due 
to the tumor or to its treatment.
Of the 63 patients studied, 25.3% (16/63) had some 
type of failure intreatment (10 local recurrences, 7 cervical 
recurrences, 1 metastasis, and 5 second primary tumors, 
for a total of 23 events in 16 patients) and 7 are still alive. 
Among the cases of failure in treatment, local or regional 
recurrence (from now on simply referred to as “recurren-
ce”) was observed in 10 cases, while distant metastases and 
the occurrence of a second primary tumor (from now on 
referred to as “others”) was observed in 5, with one patient 
had simultaneous recurrence and a second primary tumor. 
Distribution of those events was similar among the glottis (5 
recurrences and 2 others) and the supraglottic (6 recurrences 
and 4 others). There were not observed in the subglottis.
Considering only the presence of failure intreatment 
(detected in 16 cases), it can be seen that treatment failure 
occurred in 29.1% (7/24) of the glottic tumors and in 25% 
(9/36) of the supraglottic tumors. An explanation for the gre-
ater aggressiveness observed among the glottic tumors is that 
these tumors are not treated with radiotherapy or endoscopic 
surgery (a treatment indicated for earlier stages). On this basis, 
the sample of glottic tumors studied here probably consisted 
of the more aggressive fraction of these tumors.
No difference was observed between alcohol 
drinkers and non-drinkers regarding the various factors 
studied. Thus, even though alcohol has a proven role 
in the etiology of cancer of the larynx, it had no impact 
on the survival of the present patients, in contrast to the 
opinion of Dikshit et al.7.
Treatment failure occurred in 25% (2/8) of stage I 
tumors, in 12.5% (1/8) of stage II tumors, in 22.7% (5/22) of 
stage III rumors, and in 28% (7/25) of stage IV tumors. The 
failure observed in stage I concerned the glottic tumors, 
when an attempt was made to treat them by partial surgery 
of the larynx. It is known that supraglottic carcinomas have 
a different biological behavior compared to carcinomas of 
the larynx, always showing greater aggressiveness due to 
the frequent metastatization to lymph nodes, as reported 
by Greenman et al.8. However, other mechanisms are 
believed to be involved in this aggressiveness, such as a 
higher incidence of stage III and IV tumors compared to 
glottic tumors, since supraglottic tumors are diagnosed 
later when the volume of neoplastic cells is greater. In the 
present study, most supraglottic tumors were in stages III 
and IV, but did not show greater aggressiveness.
The scores in the group who had failure in treatment 
were zero+ in 75% of cases (¾), 1+ in 20% (2/10), 2+ in 
26.6% (4/15), 3+ in 20% (2/10), and 4+ in 20.1% (5/24). 
These numbers lead us to conclude that failure in treatment 
were significantly more frequent among patients with a 
zero score for the psoriasis gene. It should be emphasized 
that local recurrence is a consequence of the surgical act 
when scarce safety margins are left in the surgical bed, thus 
being related much more to the indication and execution 
of surgery than to tumor aggressiveness. This is not the 
case for regional recurrence which, although related to the 
indication and execution of cervical lymph node dissec-
tion, is due to greater tumor aggressiveness. Other failure 
associated to treatment in which erroneous indication 
of treatment is not involved are distance metastatization 
and the presence of a second primary tumor. These three 
complications, i.e., regional recurrence, metastasis and 
second primary tumor, were present in 13 cases, i.e., in 
19.4% of supraglottic tumors (7/36) and in 25% (6/24) of 
glottic tumors. They affected 8 cases with a score of less 
than 3+ (8/29 = 27.6%) and 5 cases with a score of more 
than 2+ (5/34 = 14,7%). The occurrence of statistically 
significant complications was confirmed in cases with a 
zero+ psoriasin score and the complications also tended 
to occur among patients with a score < 3+.
Of the tumors analyzed, 20.6% were well differenti-
ated, 58.7% were moderately differentiated and 20.6% were 
poorly differentiated. The distribution of cell differentiation 
was closely similar in the population of patients who pre-
sented failure in treatment, with the tumors being well dif-
ferentiated in 23% of them (3/13), moderately differentiated 
in 27% (10/37), and poorly differentiated in 30% (4/13). It 
shows that cell differentiation had no influence on failure 
in treatment. The distribution of cell differentiation was 
the same in each anatomical region. There is no evidence 
that intrinsic biological differences exist in tumors from 
these different sites. However supraglottic tumors tend to 
be more undifferentiated than glottic tumors, a fact that 
was not observed in the present study.
Psoriasin
In the present study, the expression of the psoriasin 
marker (S100 A7) was detected in 93.7% of SCCL cases, be-
ing strong in differentiated tumors and weak in poorly dif-
ferentiated ones. The more intense expression of psoriasin 
in differentiated tumors agrees with the results obtained by 
Leygue et al.9 who detected a strongly positive expression 
of psoriasin in in situ carcinomas and a lower expression in 
invasive carcinomas. These authors evaluated the expression 
of psoriasin mRNA in frozen breast tissue biopsies from in 
situ and invasive ductal carcinomas and from normal tis-
sues. More differentiated tumors are known to tend to be 
less aggressive, with a better patient course and survival. 
However, this fact was not confirmed in the present study 
since we did not detect differences in survival between the 
groups studied. Watson et al.10 reported that the expression 
of psoriasin was extensively detected in in situ tumors but 
was only expressed in 18% of invasive tumors and sug-
gested that this expression is associated with changes in 
epithelium differentiation and must play a role in early tumor 
progression. An additional factor for its involvement in the 
progression of ductal carcinoma is its location in a region 
of chromosome 1 that frequently (> 50% of cases) presents 
loss of heterozygosity in invasive tumors11.
In a recent study, Moubayed et al.4 determined the 
expression of psoriasin mRNA by RT-PCR in skin biopsies 
from patients with preneoplastic lesions, with spinocellular 
78(4) - Inglês.indb   64 07/08/2012   10:03:49
65
Brazilian Journal of otorhinolaryngology 78 (4) July/august 2012
http://www.bjorl.org  /  e-mail: revista@aborlccf.org.br
carcinomas and basocellular carcinomas and in normal 
controls. They detected increased expression in patients 
with preneoplastic lesions and with basal cell carcinoma 
and a significantly increased expression in spinocellular 
carcinoma. The authors concluded that, as is the case for 
ductal breast carcinomas and spinocellular carcinomas of 
the bladder, the increase in the expression of psoriasin must 
play an important role in the progression of skin cancer. 
Watson et al.10 also believe that psoriasin has an important 
effect on the development of the invasive phenotype, which 
may be both an indirect effect on the immune cell response 
of the host or even a direct effect contributing to tumor 
invasion. In this sample, among moderately differentiated 
tumors, expression tended to decrease with increasing 
tumor stage. The observation that 75% of the tumors with 
a zero score had failure in treatment shows that tumoral 
invasion is favored by the absence of psoriasin.
According to Zhou et al.5 calcium-binding protein 
acts on transduction and thus on the carcinogenesis of the 
epithelium, but its function has not been fully determined. 
According to Petersson et al.12 expressed psoriasin deve-
lops a phenotype of resistance to apoptosis and, according 
to Wolk et al.13 the lack of expression inhibits cell diffe-
rentitiation and increases cell motility, facilitating invasion. 
Thus, psoriasin is highly expressed in differentiated tumors 
during the pre-invasive phase and less expressed in less 
differentiated tumors and tumors in the invasive stage4. 
Krop et al.14 believe that psoriasin acts by promoting 
angiogenesis and by detaching cells that govern the anti-
-invasive function, thus explaining the high expression of 
the gene in well differentiated or estrogen-negative tumors.
According to Fukuzawa et al.15, the psoriasin gene 
acts on transcription and the segment of the gene that 
exerts this function in spinocellular carcinomas of the oral 
cavity is -1513 to 988. According to Mandal et al.16, psoriasin 
modulates the immune response favoring the growth of 
breast cancer in the initial phases. However, Zhou et al.3 
demonstrated that psoriasin acts by inhibiting, or being 
inhibited by, the beta catenin complex. Thus, according 
to these authors, in situations of high psoriasin expression 
there is a reduction of the beta catenin complex and the 
preneoplastic tissue is transformed into a well differen-
tiated spinocellular carcinoma of little aggressiveness. A 
spinocellular carcinoma will be poorly differentiated and 
highly aggressive when the expression of the beta catenin 
complex is so high as to inhibit the expression of psoriasin.
In our opinion, this gene acts on the initial phases 
of tumorigenesis, being important in the origin of diffe-
rentiated tumors. However, as the tumors become undi-
fferentiated, the influence of the gene disappears or the 
genes are consumed for the process to occur. This must 
have been the mechanism of action of the psoriasin gene 
involved in laryngeal tumors, i.e., the gene participates in 
the differentiation of the tumors and the tumors become 
more aggressive as the expression of the gene is reduced. 
The present study was the first to evaluate the expression 
of this marker in a laryngeal neoplasia and further studies 
may obtain complementary information that will make this 
gene, expressed in 93.7% of the present cases, a marker 
of the presence and aggressiveness of SCCL.
CONCLUSIONS
The psoriasin S100 A7 marker was expressed in 
93.7% of the present SCCL cases, with a higher positivity 
in well differentiated tumors, tending to decrease with in-
creasing stage in moderately differentiated tumors. Failure 
in treatment was more frequent among patients with a 
zero score, although the score had no impact on survival.
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